1707 citations
,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
June 2008 in “Drugs & therapy perspectives” Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
40 citations
,
April 1999 in “Drugs” Finasteride treats enlarged prostate, improves urinary flow, but may cause sexual side effects.
July 2018 in “Reactions Weekly” Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
March 2008 in “European Urology Supplements” Finasteride and dutasteride can affect sexual function in BPH patients.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
1 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.
1 citations
,
December 2005 in “The Journal of Urology” Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.
3 citations
,
February 2021 in “The Journal of Urology” Dutasteride can reduce night-time urination but it doesn't improve sleep quality.
January 2019 in “Actas urológicas españolas” Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
September 2018 in “Translational Andrology and Urology” March 2009 in “The Journal of Urology” Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
February 2024 in “Urology” Certain medications, especially Paroxetine, Tamsulosin, and Finasteride, are linked to ejaculatory disorders.
15 citations
,
November 2015 in “Pharmacopsychiatry” α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.
October 2006 in “Urology” Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.
August 2018 in “Daehan binyogi jong-yang haksulji” Taking sildenafil and finasteride together is safe and improves urinary and sexual symptoms in BPH patients.
14 citations
,
January 2020 in “Archivio Italiano di Urologia e Andrologia” Finasteride helps with prostate symptoms but may cause sexual side effects.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
September 2014 in “PubMed Central” BPH treatments can cause sexual side effects affecting quality of life.
12 citations
,
January 1998 in “Drug safety” Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.
97 citations
,
May 2004 in “British Journal of Urology” Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.
127 citations
,
May 2004 in “PubMed” Finasteride may help some male chronic pelvic pain patients, but more research needed.
12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
8 citations
,
August 2011 in “Journal of Medicinal Food” D-004 may be a natural alternative to finasteride for treating enlarged prostate and male baldness.
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
March 2025 in “Scientific Reports” Menthol-based microemulsions improve skin delivery of finasteride and silodosin.